HIV Infections Clinical Trial
Official title:
A Randomized Trial to Prevent HIV Among Gay Couples
The proposed study is a randomized controlled intervention to reduce sexual risk for HIV among HIV-negative concordant and HIV discordant gay couples. There are three arms of the study: 1) the in-person experimental condition, PRIDE, 2) the online adaptation of the experimental condition, ePRIDE, and 3) the time- and attention-matched in-person control condition, Men's Health. Participants (N = 300 couples) will be randomized equally into one of the three study conditions and assessed via surveys at baseline and at 3-, 6- and 9-months after completion of the intervention sessions.
Participants (N = 300 couples) will be randomized equally into one of the three study
conditions and assessed via surveys at baseline and at 3-, 6- and 9-months after completion
of the intervention sessions. All participants will complete a baseline survey, administered
a fluid (swab) OraQuick HIV test, administered a viral load (VL) or PrEP adherence dry blood
spot test using the HemaSpot collection device they will be randomized to one of three
intervention arms, and then follow-up surveys will measure short and long term impact of the
intervention at 3, 6, and 9 months.
They will first be provided with a brief overview of the study focusing on the goals of the
study, randomization, participation details and timeline, and if they wish to proceed, will
then be screened for eligibility. Our goal will be to screen and baseline cohorts of 30
couples (10 couples for each arm of the intervention) within a 6-week window (recruitment
will be on-going).
Eligible couples will be scheduled to come into the study offices to complete a baseline
survey. On arrival, couples will be informed in detail about the study and what their
participation entails. Study staff will answer any outstanding questions, informed consent
will be obtained, the participants will be given a fluid (swab) OraQuick rapid HIV test in a
private CREGS office with HIV counseling-certified staff, then will give a DBS specimen for
testing either viral load for HIV-positive participants or PrEP levels for HIV-negative
participants. For consented and eligible participants, the baseline survey will then be
administered and the baseline online survey will be administered on study computers.
On completion of the baseline survey and testing, couples will be randomized to one of the
three arms of the study (PRIDE, ePRIDE, or Men's Health). Couples will be randomized in
blocks with the block size randomly permuted via a SAS computer program based on a
pseudo-random number generator. Each arm of the intervention will begin on the same date and
run for two weeks. Couples randomized to ePRIDE will be sent a link on the same day that
PRIDE and Men's Health sessions are scheduled and will have two weeks to complete the
program. Access to ePRIDE will be deactivated at the end of two weeks.
Participants who have a positive test result for HIV during the baseline visit will be given
their results by HIV counseling-certified staff and referred for free confirmatory testing at
our nearby partner, Alliance Health Project clinic, where they will also receive clinical
care and support services. If the newly HIV-positive person is in a relationship with a
confirmed HIV-positive partner, they will be considered ineligible. If the partner is
HIV-negative, they will be eligible to participate in the study.
Short and long term impact of the intervention will be measured at 3-, 6- and 9-months post
completion of the intervention. Follow-up surveys for all three arms will be administered
online in-person at the downtown CREGS offices. Couples will be sent a link to the survey
with a unique identification number and password and will have 7 days to complete each
survey; reminders will be sent every two days contacted and scheduled to come in together to
complete follow-up surveys on provided computers. Couples who take fail to come in and
complete follow-ups longer than 7 days will be flagged so differential outcomes can be
assessed as needed and their link to the survey will be disabled after 14 days.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
Not yet recruiting |
NCT06072443 -
AURORA Study-A Transformative Approach to Support PrEP Medication Persistence
|
||
Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|